These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 416164)

  • 1. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
    Frasch CE; Robbins JD
    J Exp Med; 1978 Mar; 147(3):629-44. PubMed ID: 416164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against group B meningococcal disease. II. Infection and resulting immunity in a guinea pig model.
    Frasch CE; Robbins JD
    J Exp Med; 1978 Mar; 147(3):619-28. PubMed ID: 416163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.
    Peppler MS; Frasch CE
    Infect Immun; 1982 Jul; 37(1):264-70. PubMed ID: 6809628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model.
    Craven DE; Frasch CE
    Infect Immun; 1979 Oct; 26(1):110-7. PubMed ID: 115794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.
    Frasch CE; Parkes L; McNelis RM; Gotschlich EC
    J Exp Med; 1976 Aug; 144(2):319-29. PubMed ID: 822114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens.
    Frasch CE; Peppler MS
    Infect Immun; 1982 Jul; 37(1):271-80. PubMed ID: 6809629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children.
    Brückner S; Agnandji ST; Elias J; Berberich S; Bache E; Fernandes J; Loembe MM; Hass J; Lell B; Mordmüller B; Adegnika AA; Kremsner P; Esen M
    Vaccine; 2016 Oct; 34(44):5384-5390. PubMed ID: 27642131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of protein serotype antigens in protection against disease due to Neisseria meningitidis.
    Frasch CE
    J Infect Dis; 1977 Aug; 136 Suppl():S84-90. PubMed ID: 408436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial.
    Lieberman JM; Chiu SS; Wong VK; Partidge S; Chang SJ; Chiu CY; Gheesling LL; Carlone GM; Ward JI
    JAMA; 1996 May; 275(19):1499-503. PubMed ID: 8622225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.
    Wang LY; Frasch CE
    Infect Immun; 1984 Nov; 46(2):408-14. PubMed ID: 6437983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.
    Sáez-Llorens X; Beltran-Rodriguez J; Novoa Pizarro JM; Mensi I; Keshavan P; Toneatto D
    Hum Vaccin Immunother; 2018 May; 14(5):1161-1174. PubMed ID: 29601256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum opsonins to group B meningococci.
    Sjursen H; Bjerknes R; Halstensen A; Naess A; Frøholm LO; Rosenqvist E; Solberg CO
    Acta Pathol Microbiol Immunol Scand C; 1987 Dec; 95(6):283-9. PubMed ID: 3126623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide.
    Moreno C; Lifely MR; Esdaile J
    Infect Immun; 1985 Feb; 47(2):527-33. PubMed ID: 3917979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine.
    Frasch CE; Zahradnik JM; Wang LY; Mocca LF; Tsai CM
    J Infect Dis; 1988 Oct; 158(4):710-8. PubMed ID: 3139776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.